Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy
Brief Summary: Primary Objective:

- To demonstrate the efficacy of at least one dose of SAR110894 (H3 receptor antagonist) in comparison to placebo on cognitive performance in patients with mild to moderate Alzheimer's disease (AD) while on stable donepezil therapy

Secondary Objectives:

* To explore the effect of SAR110894 on functional impairment, global clinical status and behavioral disturbances;
* To assess the safety/tolerability of SAR110894;
* To assess pharmacokinetic (PK) of SAR110894 and concentrations of donepezil;
* To explore caregiver time consumption and distress changes.


Options:
A: Arm Label: Paracetamol or buprenorphine treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paracetamol, Drug: Buprenorphine | Arm Label: Paracetamol placebo or buprenorphine placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Paracetamol placebo, Drug: Buprenorphine placebo | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Paracetamol or buprenorphine treatment | Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): Paracetamol or buprenorphine treatment | Intervention Type: DRUG; Name: Paracetamol placebo; Assigned to Arm(s): Paracetamol placebo or buprenorphine placebo | Intervention Type: DRUG; Name: Buprenorphine placebo; Assigned to Arm(s): Paracetamol placebo or buprenorphine placebo
B: Arm Label: SAR110894 - 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: SAR110894, Drug: Donepezil | Arm Label: SAR110894 - 2 mg; Type: EXPERIMENTAL; Interventions: Drug: SAR110894, Drug: Donepezil | Arm Label: SAR110894 - 5 mg; Type: EXPERIMENTAL; Interventions: Drug: SAR110894, Drug: Donepezil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo (for SAR110894), Drug: Donepezil | Intervention Type: DRUG; Name: SAR110894; Assigned to Arm(s): SAR110894 - 0.5 mg, SAR110894 - 2 mg, SAR110894 - 5 mg | Intervention Type: DRUG; Name: placebo (for SAR110894); Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Donepezil; Assigned to Arm(s): Placebo, SAR110894 - 0.5 mg, SAR110894 - 2 mg, SAR110894 - 5 mg
C: Arm Label: Treatment Group; Type: EXPERIMENTAL; Interventions: Device: GammaSense Stimulation System (Active Settings) | Arm Label: Control Group; Type: SHAM_COMPARATOR; Interventions: Device: GammaSense Stimulation System (Sham Settings) | Intervention Type: DEVICE; Name: GammaSense Stimulation System (Active Settings); Assigned to Arm(s): Treatment Group | Intervention Type: DEVICE; Name: GammaSense Stimulation System (Sham Settings); Assigned to Arm(s): Control Group
D: Arm Label: Active Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Tailored Active intervention | Arm Label: Inactive intervention; Type: PLACEBO_COMPARATOR; Interventions: Other: Inactive intervention | Intervention Type: OTHER; Name: Tailored Active intervention; Assigned to Arm(s): Active Intervention | Intervention Type: OTHER; Name: Inactive intervention; Assigned to Arm(s): Inactive intervention

Answer: B